S&P 500   4,552.57 (-0.32%)
DOW   34,273.02 (-0.61%)
QQQ   389.24 (-1.16%)
AAPL   165.70 (+0.24%)
MSFT   332.24 (+0.50%)
FB   312.47 (-3.70%)
GOOGL   2,840.21 (+0.08%)
AMZN   3,455.37 (-1.47%)
TSLA   1,106.31 (-3.36%)
NVDA   316.53 (-3.13%)
BABA   122.20 (-4.18%)
NIO   38.60 (-1.35%)
CGC   10.08 (-5.88%)
AMD   149.78 (-5.42%)
GE   93.90 (-1.15%)
MU   85.79 (+2.13%)
T   22.32 (-2.23%)
F   19.78 (+3.07%)
DIS   142.86 (-1.41%)
PFE   54.80 (+1.99%)
AMC   28.29 (-16.65%)
ACB   6.05 (-5.76%)
BA   190.64 (-3.64%)
S&P 500   4,552.57 (-0.32%)
DOW   34,273.02 (-0.61%)
QQQ   389.24 (-1.16%)
AAPL   165.70 (+0.24%)
MSFT   332.24 (+0.50%)
FB   312.47 (-3.70%)
GOOGL   2,840.21 (+0.08%)
AMZN   3,455.37 (-1.47%)
TSLA   1,106.31 (-3.36%)
NVDA   316.53 (-3.13%)
BABA   122.20 (-4.18%)
NIO   38.60 (-1.35%)
CGC   10.08 (-5.88%)
AMD   149.78 (-5.42%)
GE   93.90 (-1.15%)
MU   85.79 (+2.13%)
T   22.32 (-2.23%)
F   19.78 (+3.07%)
DIS   142.86 (-1.41%)
PFE   54.80 (+1.99%)
AMC   28.29 (-16.65%)
ACB   6.05 (-5.76%)
BA   190.64 (-3.64%)
S&P 500   4,552.57 (-0.32%)
DOW   34,273.02 (-0.61%)
QQQ   389.24 (-1.16%)
AAPL   165.70 (+0.24%)
MSFT   332.24 (+0.50%)
FB   312.47 (-3.70%)
GOOGL   2,840.21 (+0.08%)
AMZN   3,455.37 (-1.47%)
TSLA   1,106.31 (-3.36%)
NVDA   316.53 (-3.13%)
BABA   122.20 (-4.18%)
NIO   38.60 (-1.35%)
CGC   10.08 (-5.88%)
AMD   149.78 (-5.42%)
GE   93.90 (-1.15%)
MU   85.79 (+2.13%)
T   22.32 (-2.23%)
F   19.78 (+3.07%)
DIS   142.86 (-1.41%)
PFE   54.80 (+1.99%)
AMC   28.29 (-16.65%)
ACB   6.05 (-5.76%)
BA   190.64 (-3.64%)
S&P 500   4,552.57 (-0.32%)
DOW   34,273.02 (-0.61%)
QQQ   389.24 (-1.16%)
AAPL   165.70 (+0.24%)
MSFT   332.24 (+0.50%)
FB   312.47 (-3.70%)
GOOGL   2,840.21 (+0.08%)
AMZN   3,455.37 (-1.47%)
TSLA   1,106.31 (-3.36%)
NVDA   316.53 (-3.13%)
BABA   122.20 (-4.18%)
NIO   38.60 (-1.35%)
CGC   10.08 (-5.88%)
AMD   149.78 (-5.42%)
GE   93.90 (-1.15%)
MU   85.79 (+2.13%)
T   22.32 (-2.23%)
F   19.78 (+3.07%)
DIS   142.86 (-1.41%)
PFE   54.80 (+1.99%)
AMC   28.29 (-16.65%)
ACB   6.05 (-5.76%)
BA   190.64 (-3.64%)
NYSE:PKI

PerkinElmer Stock Forecast, Price & News

$185.54
+3.38 (+1.86%)
(As of 12/1/2021 03:33 PM ET)
Add
Compare
Today's Range
$179.41
$187.12
50-Day Range
$166.66
$188.82
52-Week Range
$119.95
$192.00
Volume
24,970 shs
Average Volume
834,924 shs
Market Capitalization
$23.42 billion
P/E Ratio
18.46
Dividend Yield
0.15%
Beta
1.06
30 days | 90 days | 365 days | Advanced Chart
Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.


PerkinElmer logo

About PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Headlines

PerkinElmer (NYSE:PKI) Shares Up 5%
November 26, 2021 |  americanbankingnews.com
PerkinElmer (NYSE:PKI) Shares Gap Down to $188.82
November 23, 2021 |  americanbankingnews.com
PerkinElmer (NYSE:PKI) Releases Q4 2021 Earnings Guidance
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
71404610
Employees
2,019
Year Founded
1937

Sales & Book Value

Annual Sales
$3.78 billion
Cash Flow
$10.96 per share
Book Value
$55.14 per share

Profitability

Net Income
$727.89 million
Pretax Margin
28.50%

Debt

Price-To-Earnings

Miscellaneous

Free Float
125,506,000
Market Cap
$23.42 billion
Optionable
Optionable

Company Calendar

Ex-Dividend
10/21/2021
Last Earnings
11/02/2021
Dividend Payable
11/12/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/01/2022

Social Links


MarketRank

Overall MarketRank

2.39 out of 5 stars

Computer And Technology Sector

202nd out of 892 stocks

Analytical Instruments Industry

7th out of 33 stocks

Analyst Opinion: 1.5Community Rank: 4.4Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












PerkinElmer (NYSE:PKI) Frequently Asked Questions

Is PerkinElmer a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PerkinElmer stock.
View analyst ratings for PerkinElmer
or view top-rated stocks.

How has PerkinElmer's stock price been impacted by COVID-19 (Coronavirus)?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PKI shares have increased by 154.7% and is now trading at $185.54.
View which stocks have been most impacted by COVID-19
.

Are investors shorting PerkinElmer?

PerkinElmer saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,610,000 shares, an increase of 32.2% from the October 31st total of 2,730,000 shares. Based on an average daily volume of 677,900 shares, the days-to-cover ratio is currently 5.3 days.
View PerkinElmer's Short Interest
.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for PerkinElmer
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) issued its earnings results on Tuesday, November, 2nd. The medical research company reported $2.31 EPS for the quarter, topping the consensus estimate of $1.70 by $0.61. The medical research company earned $1.17 billion during the quarter, compared to the consensus estimate of $1 billion. PerkinElmer had a trailing twelve-month return on equity of 30.57% and a net margin of 22.41%. During the same quarter in the previous year, the business earned $2.09 EPS.
View PerkinElmer's earnings history
.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Wednesday, October 27th. Stockholders of record on Friday, January 21st will be paid a dividend of $0.07 per share on Friday, February 11th. This represents a $0.28 dividend on an annualized basis and a yield of 0.15%. The ex-dividend date is Thursday, January 20th.
View PerkinElmer's dividend history
.

Is PerkinElmer a good dividend stock?

PerkinElmer pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.15%. The dividend payout ratio of PerkinElmer is 2.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PerkinElmer will have a dividend payout ratio of 4.42% next year. This indicates that PerkinElmer will be able to sustain or increase its dividend.
View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of $10.810-$10.810 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.070. The company issued revenue guidance of $4.90 billion-$4.90 billion, compared to the consensus revenue estimate of $4.65 billion.

What price target have analysts set for PKI?

6 Wall Street analysts have issued 1 year target prices for PerkinElmer's stock. Their forecasts range from $50.00 to $206.00. On average, they anticipate PerkinElmer's share price to reach $155.98 in the next year. This suggests that the stock has a possible downside of 15.9%.
View analysts' price targets for PerkinElmer
or view top-rated stocks among Wall Street analysts.

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Prahlad Ramadhar Singh, President, CEO, COO & Director
  • James M. Mock, Chief Financial Officer & Senior Vice President
  • Andrew Okun, Chief Accounting Officer & Vice President
  • Bryan A. Kipp, VP & General Manager-Life Sciences Integration
  • Joel S. Goldberg, Secretary, SVP-Administration & General Counsel

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer CEO Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among PerkinElmer's employees.

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (9.98%), BlackRock Inc. (6.64%), Massachusetts Financial Services Co. MA (3.76%), Janus Henderson Group PLC (1.79%), Geode Capital Management LLC (1.83%) and Goldman Sachs Group Inc. (1.40%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Peter Barrett, Prahlad R Singh and Sylvie Gregoire.
View institutional ownership trends for PerkinElmer
.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, State of Michigan Retirement System, Alta Capital Management LLC, Massachusetts Financial Services Co. MA, SG Americas Securities LLC, Pura Vida Investments LLC, Balyasny Asset Management LLC, and Balyasny Asset Management LLC. Company insiders that have sold PerkinElmer company stock in the last year include Andrew Okun, Daniel R Tereau, James M Mock, Prahlad R Singh, and Sylvie Gregoire.
View insider buying and selling activity for PerkinElmer
or view top insider-selling stocks.

Which major investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Capital Research Global Investors, Alliancebernstein L.P., Goldman Sachs Group Inc., Blue Water Life Science Advisors LLC, Panagora Asset Management Inc., Morgan Stanley, and Man Group plc.
View insider buying and selling activity for PerkinElmer
or or view top insider-buying stocks.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $185.54.

How much money does PerkinElmer make?

PerkinElmer has a market capitalization of $23.42 billion and generates $3.78 billion in revenue each year. The medical research company earns $727.89 million in net income (profit) each year or $10.05 on an earnings per share basis.

How many employees does PerkinElmer have?

PerkinElmer employs 2,019 workers across the globe.

Does PerkinElmer have any subsidiaries?

The following companies are subsidiares of PerkinElmer: Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Longrun Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, Bioo Scientific Corporation, Biosense Picolabs Inc., Biosense Technologies Pvt Ltd., Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Chromo G.A. SAS, CisBio US Inc., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio Group SAS, Cisbio KK, Cisbio.com, DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, EUROIMMUN (Hangzhou) Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN (South East Asia) Pte Ltd., EUROIMMUN (Tianjin) Medical Diagnostic Technology Co. Ltd., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnóstica Ltda., EUROIMMUN Diagnostics España S.L.U., EUROIMMUN France SAS, EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics (China) Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Laboratory Diagnostics South Africa (Pty) Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Spólka z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.S., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Discovery, Immunodiagnostic Systems, Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, ManCell SAS, Nexcelom Bioscience, NovaScreen Biosciences Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Immunotec, Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin Elmer de Mexico S.A., Perkin-Elmer Argentina S.R.L., Perkin-Elmer Instruments (Philippines) Corporation, PerkinElmer (Hong Kong) Ltd., PerkinElmer (India) Pvt Ltd., PerkinElmer (Ireland) Ltd., PerkinElmer (Schweiz) AG, PerkinElmer (Shanghai) Equity Investment Fund L.P., PerkinElmer (Shanghai) Equity Investment Fund Management Co. Ltd., PerkinElmer (UK) Holdings Ltd., PerkinElmer Analytical Solutions B.V., PerkinElmer Automotive Research Inc., PerkinElmer BVBA, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.à r.l., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences (Australia) Pty. Ltd., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics (Shanghai) Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Pty. Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer Informatics Inc., PerkinElmer Instruments (Suzhou) Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS (Germany) GmbH, PerkinElmer LAS (UK) Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management (Shanghai) Co. Ltd., PerkinElmer Nederland B.V., PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Shared Services Sp z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa (Pty) Ltd., PerkinElmer Sverige AB, PerkinElmer Sweden Health Sciences Holdings AB, PerkinElmer Taiwan Corporation, PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments (Beijing) Co. Ltd., Perten Instruments AB, Perten Instruments France SASU, Perten Instruments GmbH, Perten Instruments Italia S.r.l., Perten Instruments of Australia Pty Ltd., RHS Ltd, RayAl Ltd., Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Solus Scientific Solutions Inc., Solus Scientific Solutions Ltd., Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.

When was PerkinElmer founded?

PerkinElmer was founded in 1937.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

Where are PerkinElmer's headquarters?

PerkinElmer is headquartered at 940 WINTER STREET, WALTHAM MA, 02451.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at (781) 663-6900, via email at [email protected], or via fax at 781-663-5985.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.